2009 Symposium on Drug Design, Discovery and Delivery

The Symposium on Drug Design, Discovery and Delivery will be held on October 14-16, 2009 at the Blase Alfano Center across Fowler from the Research Park.

The technical committee has an impressive line-up of speakers that includes:
 
David Lawrence (UNC Chapel Hill)
Anabella Villalobos (Pfizer)
Lanny Liebeskind (Emory)
Bill Roush (Scripps Florida)
George Newkome (Univ of Akron)
Gary Molander (Penn)
John Porco (Boston Univ)
Gregory Roth (Burnham Institute)
Michael Gelb (Univ. of Washington)
Amina Woods (NIH)
Chuan He  (University of Chicago)
David Newman (NIH)
Gary Strobel (Montana State)

Larry Gold (Somalogic) has agreed to be the Plenary Speaker.  A brief biography for Dr. Gold is given below.

Dr. Larry Gold is the founder, Chairman of the Board, and Chief Executive Officer of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.
During nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including Chairman of the Board, Executive VP of R&D, and Chief Science Officer. Before forming NeXagen, he also co-founded and served as co-Director of Research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc.
Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder (CU). While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992.
During his prestigious career, Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology. In addition, Dr. Gold has been a member of the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995.
Dr. Gold also serves on the board of directors of BioForce Nanosystems, BT Pharma, CompleGen, MicroPhage, and the scientific advisory board of Archemix.

We also have many vendors that have already committed to exhibit at this year's symposium.  All of the vendors returning from last year had profuse positive feedback regarding the excellent interactions they were able to engage in at last year's symposium.
The companies that have already promised to participate are:

• ThermoFisher
• VWR
• Eppendorf
• Micro Optics
• Promega Corporation
• Invitrogen
• Sigma Aldrich
• KPL
• Varian

Any other suggestions of companies that should be invited are welcome and encouraged.

Attendee Registration (Word doc format)